Overview

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China

Phase:

N/A

Details

Lead Sponsor:

AIM Vaccine Co., Ltd.

Collaborators:

First Affiliated Hospital Bengbu Medical College
Ningbo Rongan Biological Pharmaceutical Co. Ltd

Treatments:

Vaccines